BioCanada

Found 26,039 articles

• Statement from the Chief Public Health Officer of Canada on September 20, 2020

  9/20/2020

  In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement

• Statement from the Chief Public Health Officer of Canada on September 19, 2020

  9/19/2020

  In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement

• Adastra Signs LOI to Acquire Iconic Legacy Market Phyto Extractions Brands

  9/18/2020

  Adastra Labs Holdings Ltd. (CSE:XTRX)(FRANKFURT:D2EP) ("Adastra") a Health Canada Licensed cannabis processing and analytical testing services Company, is pleased to announce it has signed a Letter of Intent ("LOI") for the acquisition of Phyto Extractions Brands ("Phyto Extractions").

• Pardeep Nijhawan Acquires Beneficial Ownership of Additional Securities of Edesa Biotech, Inc.

  9/18/2020

  Dr. Pardeep Nijhawan announces that his beneficial ownership of common shares in the capital of Edesa Biotech, Inc. has increased by more than 2% of the issued and outstanding Common Shares from the amount reported in the early warning report Dr. Nijhawan filed dated May 11, 2020.

• Dr. Joanne Langley to serve as new senior medical advisor for Meningitis Research Foundation of Canada

  9/18/2020

  The Meningitis Research Foundation of Canada extends a warm welcome to its new senior medical advisor, Dr. Joanne Langley.

• Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study

  9/18/2020

  Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix

• StageZero Life Sciences Announces Share Consolidation Completion

  9/18/2020

  StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Corporation") announced that trading of the common shares on the TSX on a post-Consolidation basis commences at market open on September 18, 2020.

• Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study

  9/18/2020

  Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline Significantly Fewer Overall Adverse Events Were Reported in Cytisinicline-Treated Subjects (p<0.001) Cytisinicline U.S. Phase 3 Trial Expected to Begin in Fourth Quarter 2020   [18-September-2020]   SEATTLE and VANCOUVER,

• Radient Conducts Strategic Review of Operations and Announces Management Changes

  9/18/2020

  Radient Technologies Inc. (“Radient” or the “Company”) (TSX-V:RTI; OTCQX:RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, announces its Board of Directors (the “Board”) is conducting a strategic review of the Company’s operations targeting a path to positive cash flow by evaluating costs and under utilized assets.

• Statement from CMA president on Canada's Premiers Health Care Priorities

  9/18/2020

  The CMA agrees with Canada's Premiers that additional federal funding is urgently needed to address the immense pressures on our health care system.

• Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results

  9/18/2020

  Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF)   is pleased to announce that it has entered into a consulting agreement (the “ Consulting Agreement ”) with Adelaide Capital (“ Adelaide ”) to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the “ TSXV ”) and applicable legislation. Adelaide will

• Advisory - Unauthorized health products sold on Steroid Hub Canada website may pose serious health risks

  9/18/2020

  Issue Health Canada is warning Canadians about the online retailer Steroid Hub Canada because it is selling unauthorized health products that may pose serious health risks.

• Appili Therapeutics Virtually Opens The Market

  9/18/2020

  Dr. Armand Balboni , CEO, Appili Therapeutics Inc. (TSX: APLI), joined his team and Sophie Van Houtte , Head, Company Services, TMX Group, to celebrate the company's graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market.  Appili Therapeutics Inc. was founded to advance the global fight against infectious d

• 

  BioSpace Global Roundup, Sept. 17

  9/17/2020

  Companies from across the globe provide updates on their businesses and pipelines.

• ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020

  9/17/2020

  ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of data of ESSA's clinical candidate, EPI-7386, at the ESMO Virtual Congress 2020. 

• Highland Therapeutics Announces New Chief Commercial Officer and Appointment of Chief Scientific Officer

  9/17/2020

  Highland Therapeutics Inc. (“Highland”) today announced two executive appointments at its wholly owned subsidiaries. Mr. Danny Villeneuve has assumed the role of Executive Vice President and Chief Commercial Officer and Dr. Bev Incledon has been promoted to the role of Executive Vice President and Chief

• Titan Medical Announces Intellectual Property Portfolio Expansion with Issuance of Robotic Surgery Patents Related to Camera and System Control

  9/17/2020

  Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of single-port robotic surgical technologies, announces that it has recently been issued two U.S. patents, increasing its global intellectual property portfolio to 58 issued patents and 84 patent applications. The Company has also received notices of allowance in 17 other patent applications

• Tetra Bio-Pharma Adds Two Board Members and Appoints New COO

  9/17/2020

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP.TO) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Ms. Dale Weil and Dr. Brent Norton have been appointed to the Company's Board of Directors and Dr. Graham Wood, Ph.D. has been appointed as Chief Operating Officer.

• ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

  9/17/2020

   IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,  announce a research collaboration with Zymeworks Inc., giving ImmunoPrecise access to  Zymeworks' Azymetric™ and EFECT™ platforms for the

• Statement from the Chief Public Health Officer of Canada on September 17, 2020

  9/17/2020

  In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement